Most Promising Therapies in Interventional Cardiology

• Published in: Current cardiology reports Vol. 21; no. 4; p. 26
• Main Authors: Kerneis, Mathieu, Nafee, Tarek, Yee, Megan K., Kazmi, Hassan A., Datta, Sudarshana, Zeitouni, Michel, Afzal, M. Khurram, Jafarizade, Mehrian, Walia, Sargun S., Qamar, Iqra, Pitliya, Anmol, Kalayci, Arzu, Al Khalfan, Fahad, Gibson, C. Michael
• Format: Journal Article
• Language: English
• Published: New York Springer US 01.04.2019; Current Medicine Group
• Subjects: Cardiac Catheterization; Cardiology; Cardiology - trends; Cardiology and cardiovascular system; Coronary Artery Disease - therapy; Human health and pathology; Humans; Life Sciences; Medicine; Medicine & Public Health; New Therapies for Cardiovascular Disease (AA Bavry; Percutaneous Coronary Intervention; Registries; Section Editor; Topical Collection on New Therapies for Cardiovascular Disease; Percutaneous coronary intervention; Implantable device; Acute coronary syndrome; Coronary artery disease
• ISSN: 1523-3782; 1534-3170; 1543-3170
• DOI: 10.1007/s11886-019-1108-x

Purpose of Review The last 40 years of clinical research in interventional cardiology were extraordinarily innovative. This article will review the most promising up and coming interventional cardiovascular therapies, with a primary focus on the treatment of coronary artery disease. Recent Findings From the first stent, to the first transcatheter aortic valve implantation (TAVI), and the left appendage closure technique, percutaneous interventions revolutionized the treatment of multiple diseases and dramatically improved the prognosis of many patients. While these advances have decreased the risk of mortality in some patients (such as ST-elevation myocardial infarction), 15% of acute coronary syndrome (ACS) patients still experience recurrent ischemic events within the first year, challenging us to develop new pharmaceutical targets and new devices. Summary The continued emergence of data supporting inflammation as a risk factor and pharmacologic target as well as data supporting the importance of cholesterol efflux have identified novel therapeutic targets that may play a major role in the improvement of prognosis of patients with coronary artery disease. In addition, novel medical devices are being developed to allow even earlier detection of acute cardiac events and to support high-risk percutaneous coronary interventions. Advances in computing and the ability to analyze large datasets will allow us to use artificial intelligence to augment the clinician patient experience, both in and out of the catheterization laboratory, with live procedural guidance as well as pre- and post-operative prognostication tools.